Pharma Mar (PHMMF) Projected to Announce Quarterly Earnings on Wednesday

Pharma Mar (OTCMKTS:PHMMF) is projected to post its resultson Wednesday, July 29th. Analysts expect Pharma Mar to post earnings of $0.2027 per share and revenue of $50.4790 million for the quarter.

Pharma Mar Price Performance

OTCMKTS PHMMF opened at $86.09 on Wednesday. Pharma Mar has a 52-week low of $77.41 and a 52-week high of $110.40. The company has a fifty day moving average of $93.21 and a 200-day moving average of $93.90. The company has a quick ratio of 2.44, a current ratio of 3.02 and a debt-to-equity ratio of 0.14.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. BTIG Research started coverage on Pharma Mar in a research note on Thursday, April 23rd. They set a “buy” rating for the company. Zacks Research raised Pharma Mar to a “hold” rating in a report on Monday, June 15th. Finally, Chardan Capital upgraded Pharma Mar to a “strong-buy” rating in a research report on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Buy”.

Pharma Mar Company Profile

PharmaMar is a Spain-based biopharmaceutical company that specializes in the discovery and development of novel oncology therapies derived from marine organisms. Founded in 1986 as part of Grupo Zeltia, the company has pioneered the use of compounds extracted from deep-sea organisms to create synthetic analogs aimed at treating various forms of cancer. Its core expertise lies in marine biotechnology, medicinal chemistry and oncology-focused clinical development.

The company’s flagship product is Yondelis (trabectedin), an antitumor agent approved in the European Union for the treatment of soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer.